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Abstract
Background: The choice of vasopressor use in the intensive care unit (ICU) depends primarily on provider
preference. This study aims to describe the rate of vasopressor utilization and the trends of each vasoactive agent
usage in the ICU over the span of 7 years in a tertiary referral center.
Methods: All adult ICU admissions, including medical, cardiac, and surgical ICUs from January 1st, 2007 through
December 31st, 2013 were included in this study. Vasopressor use was defined as the continuous intravenous
administration of epinephrine, norepinephrine, phenylephrine, dopamine, or vasopressin within a given ICU day.
The vasopressor utilization index (VUI) was defined as the proportion of ICU days on each vasoactive agent divided
by the total ICU days with vasopressor usage.
Results: During the study period, 72,005 ICU admissions and 272,271 ICU days were screened. Vasopressors
were used in 19,575 ICU admissions (27 %) and 59,811 ICU days (22 %). Vasopressin was used in 24,496 (41 %),
epinephrine in 23,229 (39 %), norepinephrine in 20,648 (34 %), dopamine in 9449 (16 %), and phenylephrine in 7508
(13 %) ICU days. The VUInorepinephrine increased from 0.24 in 2007 to 0.46 in 2013 and VUIphenylephrine decreased from
0.20 in 2007 to 0.08 in 2013 (p < 0.001 both). For epinephrine, dopamine, and vasopressin VUI did not change over
the course of study.
Conclusion: Vasopressors were used in about one fourth of ICU admissions and about one-fifth of ICU days.
Although vasopressin is the most commonly used vasopressor, the use of norepinephrine found to have an
increasing trajectory.
Keywords: Intensive care unit, Shock, Vasopressors, Epinephrine, Norepinephrine, Phenylephrine, Dopamine,
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Background
Circulatory shock is defined as mismatch among oxygen
delivery and tissue consumption which leads to end-
organ damage, multisystem organ failure, and potentially
death [1, 2]. Patients with circulatory shock commonly
present with hypotension. Intravascular fluids and vaso-
active agents are often used in the management of these
patients. Vasoactive medications which entered clinical
practice as of the 1940s are able to increase blood pres-
sure by their vasoconstrictive capabilities.
Between four main types of circulatory shock (hypo-
volemic, cardiogenic, distributive and obstructive), dis-
tributive shock due to sepsis is one the most common
forms and is a leading cause of death in non-coronary
intensive care units (ICU). Its incidence has been in-
creasing annually [3, 4]. Mortality rate in ICU patients
with septic shock ranges from 35 to 60 % [5–7]. In the
United States, septic shock is responsible for greater
than 200,000 deaths per year [8]. Following optimum
fluid resuscitation, treatment with vasoactive agents be-
gins in an effort to restore tissue oxygen delivery and
* Correspondence: kashani.kianoush@mayo.edu
1Division of Nephrology and Hypertension, Mayo Clinic, 200 First Street SW,
Rochester, MN 55905, USA
3Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester,
MN, USA
Full list of author information is available at the end of the article
© 2016 Thongprayoon et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Thongprayoon et al. BMC Pharmacology and Toxicology  (2016) 17:19 
DOI 10.1186/s40360-016-0063-z
normalize cellular function [9, 10]. The Surviving Sepsis
Campaign guidelines for septic shock recommend a
mean arterial pressure (MAP) of ≥65 mmHg to achieve
adequate end-organ perfusion [11]. Vasoactive agents
such as epinephrine, norepinephrine, phenylephrine,
dopamine, and vasopressin have increasingly become an
integrated therapeutic cornerstone for the management
of septic shock. Following the publication of the early
goal-directed therapy (EGDT) paper in 2001 [12], there
have been a large number of clinical trials with a focus
on the efficacy and adverse effects of vasoactive agents
for the management of shock [13–23]. Despite the wide-
spread use of vasoactive agents, there are only small
numbers of randomized clinical trials to compare their
efficacy. In a recent systematic analysis, authors were
able to find 23 controlled trials focused on vasopressors
[24]. Investigators concluded there was no evidence to
support differences among the examined vasopressors.
On the other hand, guidelines for the management of
circulatory shock have emphasized the use of some of
the vasopressors in certain conditions based on their
physiology, animal data, and expert opinions.
It is critical to understand the rate of vasopressor
utilization and the temporal trend of vasopressor use for
the management of shock. This would allow the scien-
tific community to have access to a broader view of
current practices and changes over the course of recent
years. Thus, we conducted a study to describe the tem-
poral changes in the utilization of vasoactive agents in
the ICU setting.
Methods
Study population and setting
This is a descriptive study investigating the use of vari-
ous vasopressors in the ICU setting at a tertiary referral
hospital system. All adult ICU admissions of >18 years
old from January 1st, 2007 through December 31st, 2013
were examined at Mayo Clinic Hospital in Rochester,
MN. Patients without research authorization were ex-
cluded. The Mayo Clinic Institutional Board Review ap-
proved this study (#14-002385) and waived the consent
for patients who had a research authorization.
The Mayo Clinic Rochester Hospital system consists
of the Rochester Methodist (342 inpatient beds) and
Saint Marys (946 inpatient beds) campuses. Because of
the geographic distance between Mayo Clinic and the
nearest non-Mayo Clinic ICU, critical care services to the
local population are provided exclusively by the Mayo
Clinic Rochester Hospital system. This system consists of
a total of 138 adult closed ICU beds (Additional file 1:
Table S1). Critical care specialists from internal medicine,
anesthesiology, and/or surgery background manage and
co-manage patients in all ICUs. During the study period,
there was no enterprise-level protocol or guideline for
vasopressor selection implemented in our ICUs. Thus,
vasopressor choices were determined by treating physi-
cians, although, multidisciplinary care provided in our
ICUs partly constrains individualized choices for vaso-
active agents.
Data collection
Clinical characteristics and the use of vasopressors was
collected using automated retrieval from the institutional
electronic medical record system. The use of vasopres-
sors within a given ICU day (12:00 am to 11:59 pm)
throughout ICU stay was reviewed. Vasopressor
utilization was defined as the continuous intravenous in-
fusion of epinephrine, norepinephrine, phenylephrine,
dopamine, or vasopressin, regardless of dosage. Low-
dose dopamine was defined as continuous intravenous
administration of dopamine at a rate of <3 mcg/kg/min.
The number of ICU days on any vasopressor (vasopres-
sor day) and the number of ICU days on each vasopres-
sor were collected. The use of each vasopressor was
reported as the vasopressor utilization index (VUI),
using the following formula:
Vasopressor utilization index VUIð Þ
¼ The total number of ICU days on a given vasopressor
The total number of ICU days on any vasopressor
An electronic data extraction algorithm was developed
to search for the use of vasopressors within a given ICU
day using data from a custom relational research data-
base, which contains a near real-time copy of clinical
data from the electronic medical record [25]. This data-
base stores pertinent fluid input/output and Medication
Administration Record data within an average of 15 min
from entry into the medical record and serves as the
data repository for data rules development.
To validate the accuracy of the electronic data extrac-
tion algorithm, 300 ICU patients were randomly se-
lected, and comprehensive medical record review was
performed for the use of vasopressors within a given
ICU day. The algorithm has 97 % sensitivity and 100 %
specificity, resulting in a positive predictive value of 100 %
and a negative predictive value of 99.6 % (Additional file 1:
Table S2).
Statistical analysis
Continuous variables were reported as mean ± standard
deviation (SD) for normally distributed data and median
with interquartile range (IQR) for skewed data. Categor-
ical variables were reported as counts and percentages.
We calculated VUI for each vasopressor (i.e. epineph-
rine, norepinephrine, phenylephrine, dopamine, and
vasopressin). The trend in the use of each vasopressor in
each year from 2007 through 2013 was graphically
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represented. The annual changes in the rates of VUI
were modeled using negative binomial regression (MASS
package, Venables, and Ripley, 2002). An offset was uti-
lized in the models to account for the differences in total
days of vasopressor use. The analysis was performed in
all ICUs and subgroup analysis in each ICU type (med-
ical, surgical, cardiac surgical, cardiac care units, and
mixed). P-values of < .05 were considered statistically
significant. All analyses were performed using JMP
statistical software (version 10, SAS, Cary, NC) and R
(version 3.1.1; Vienna, Austria).
Results
From 2007 to 2013, we identified 72,005 ICU admissions
and 272,271 ICU days. The median ICU length of stay
was 2 (IQR 2–4) days. ICU and in-hospital mortality
were 4 and 7 %, respectively. There were no clinically
significant differences in characteristics or outcomes
among patients admitted to the ICU over the study
period (Table 1).
Vasopressors were used in 19,575 of ICU admissions
(27 %) and 59,811 ICU days (22 %). Vasopressors were
most commonly employed in the cardiac surgery ICU
(55 % of ICU admissions and 47 % of total ICU days).
The vasopressor utilization rate in other ICUs was from
17 to 24 % of ICU admissions and 12 to 23 % of ICU
days (Table 2).
Vasopressor utilization in all ICUs
Out of 59,811 vasopressor days, vasopressin was used in
24,496 (41 %), epinephrine in 23,229 (39 %), norepineph-
rine in 20,648 (34 %), dopamine in 9449 (16 %) and
phenylephrine in 7508 (13 %) days. From 2007 to 2013,
there was an increasing trend in the use of norepineph-
rine (VUInorepinephrine was 0.24 in 2007 and 0.46 in 2013;
p < 0.001) and a decreasing trend in the use of phenyl-
ephrine (VUIphenylephrine was 0.20 in 2007 and 0.08 in
2013; p < 0.001). Epinephrine, dopamine, and vasopressin
utilization trends did not change (Table 3, Additional
file 1: Table S3, Figs. 1 and 2). During this period, signifi-
cant studies and guidelines with the potential effect on
VUI were published (Fig. 1).
Vasopressor use in the cardiac surgery ICU
Out of 25,710 vasopressor days, epinephrine was used in
18,354 (71 %), vasopressin in 12,367 (48 %), norepineph-
rine in 3838 (15 %), dopamine in 3494 (14 %), and
phenylephrine in 905 (4 %) days. From 2007 to 2013,
there was an increasing trend in the use of norepineph-
rine (VUInorepinephrine was 0.02 in 2007 and 0.27 in 2013;
p < 0.001) and vasopressin (VUIvasopressin was 0.34 in
2007 and 0.59 in 2013; p < 0.001). There was a decreas-
ing trend in the use of epinephrine (VUIepinephrine was
0.73 in 2007 and 0.65 in 1013; p = 0.001), phenylephrine
(VUIphenylephrine was 0.07 in the year 2007 and 0.02 in
the year 2013; p < 0.001), and dopamine (VUIdopamine
Table 1 Clinical characteristics
Characteristics Total Year
2007 2008 2009 2010 2011 2012 2013
N 72,005 10070 10373 10006 10265 10682 10473 10136
Age, year (mean ± SD) 63 ± 17 63 ± 17 63 ± 17 63 ± 17 63 ± 17 63 ± 17 63 ± 17 63 ± 17
Male sex, n (%) 41,633 (58) 5741 (57) 5953 (57) 5889 (59) 5928 (58) 6205 (58) 6004 (57) 5913 (58)
White, n (%) 66,007 (92) 9117 (91) 9356 (90) 8959 (90) 9452 (92) 9969 (93) 9739 (93) 9415 (93)
BMI, kg/m2 (mean ± SD) 29.8 ± 8.0 29.6 ± 7.8 29.6 ± 8.0 29.8 ± 8.1 29.8 ± 8.0 29.8 ± 7.9 29.9 ± 7.9 30.0 ± 8.1
ICU type (%)
- Cardiac surgery ICU 15,631 (22) 2055 (20) 2104 (20) 2220 (22) 2415 (24) 2257 (21) 2246 (21) 2334 (23)
- Cardiac care unit 8,807 (12) 1372 (14) 1327 (13) 1247 (12) 1206 (12) 1310 (12) 1162 (11) 1183 (12)
- Medical ICU 16,863 (23) 2202 (22) 2315 (22) 2323 (23) 2431 (24) 2527 (24) 2540 (24) 2525 (25)
- Surgical ICU 19,997 (28) 2825 (28) 3046 (29) 2773 (28) 2893 (28) 2908 (27) 2921 (28) 2631 (26)
- Mixed ICU 10,707 (15) 1616 (16) 1581 (15) 1443 (14) 1320 (13) 1680 (16) 1604 (15) 1463 (14)
Admission SOFA score (median, IQR) 4 (2–7) 4 (2–7) 4 (2–7) 4 (2–7) 4 (2–7) 4 (2–7) 4 (2–7) 4 (2–7)
Admission APACHE III score (mean ± SD) 67 ± 26 66 ± 27 67 ± 26 67 ± 26 67 ± 25 68 ± 26 67 ± 26 65 ± 25
Mechanical ventilator use in ICU, n (%) 28,844 (40) 4061 (40) 4214 (41) 4183 (42) 4237 (41) 4138 (39) 3904 (37) 4107 (41)
ICU length of stay, day (median, IQR) 2 (2–4)
ICU mortality, n (%) 2,755 (4) 426 (4) 447 (4) 377 (4) 353 (3) 419 (4) 360 (3) 373 (4)
In-hospital mortality, n (%) 4,896 (7) 730 (7) 816 (8) 646 (6) 615 (6) 752 (7) 664 (6) 673 (7)
BMI body mass index, SOFA score the sequential organ failure assessment score, APACHE III score the acute physiology and chronic health evaluation III score
Demographic and baseline characteristics of all patients admitted to all ICUs from January 1st, 2007 to December 31st, 2013
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was 0.16 in 2007 and 0.10 in 2013; p = 0.03) (Additional
file 1: Table S4A and Fig. 3a).
Vasopressor use in the cardiac care unit
Out of 9310 vasopressor days, dopamine was used in
4623 (50 %), epinephrine in 3495 (38 %), vasopressin in
2662 (29 %), norepinephrine in 1638 (18 %), and phenyl-
ephrine in 565 (6 %) days. From 2007 to 2013, there
was an increasing trend in the use of norepinephrine
(VUInorepinephrine was 0.11 in 2007 and 0.22 in 2013;
p < 0.001). There was a decreasing trend in the use of
epinephrine (VUIepinephrine was 0.44 in 2007 and 0.36
in 2013; p = 0.002) and phenylephrine (VUIphenylephrine
was 0.09 in 2007 and 0.04 in 2013; p < 0.001). Vaso-
pressin and dopamine utilization trends did not
change (Additional file 1: Table S4B and Fig. 3b).
Vasopressor use in the medical ICU
Out of 8397 vasopressor days, norepinephrine was used
in 6651 (79 %), vasopressin in 2409 (29 %), phenyleph-
rine in 860 (10 %), dopamine in 716 (9 %), and epineph-
rine in 473 (6 %) days. From 2007 to 2013, there was an
increasing trend in the use of norepinephrine (VUInorepi-
nephrine was 0.67 in 2007 and 0.87 in 2013; p < 0.001) and
epinephrine (VUIepinephrine was 0.03 in 2007 and 0.07 in
2013; p < 0.001). There was a decreasing trend in the use
of phenylephrine (VUIphenylephrine was 0.15 in 2007 and
0.07 in 2013; p = 0.04), vasopressin (VUIvasopressin was
0.44 in 2007 and 0.26 in 2013; p = 0.001), and dopa-
mine (VUIdopamine was 0.15 in 2007 and 0.04 in 2013;
p < 0.001), (Additional file 1: Table S4C and Fig. 3c).
Vasopressor use in the surgical ICU
Out of 10,533 vasopressor days, vasopressin was used in
4817 (46 %), norepinephrine in 4357 (41 %), phenyleph-
rine in 3673 (35 %), epinephrine in 599 (6 %) and dopa-
mine in 349 (3 %) days. From 2007 to 2013, there was
an increasing trend in the use of norepinephrine
(VUInorepinephrine was 0.28 in 2007 and 0.58 in 2013;
p < 0.001). There was a decreasing trend in the use of
phenylephrine (VUIphenylephrine was 0.39 in 2007 and
0.30 in 2013; p = 0.02), vasopressin (VUIvasopressin was
0.53 in 2007 and 0.40 in 2013; p = 0.01) and dopa-
mine (VUIdopamine was 0.06 in 2007 and 0.01 in 2013;
p < 0.001). Epinephrine utilization trend did not
change (Additional file 1: Table S4D and Fig. 3d).
Vasopressor use in the mixed medical/surgical ICU
Out of 5861 vasopressor days, norepinephrine was used in
4164 (71 %), vasopressin in 2241 (38 %), phenylephrine in
1505 (26 %), epinephrine in 308 (5 %), and dopamine in
267 (5 %) days. From 2007 to 2013, there was an increas-
ing trend of norepinephrine (VUInorepinephrine was 0.51 in
2007 and 0.88 in 2013; p < 0.001) and epinephrine
Table 2 Proportion of ICU patients with vasopressor use divided by total ICU admission and proportion of total ICU day on
vasopressor over total ICU day
ICU admission (n) Patients on vasopressor, n (%) ICU day (n) Vasopressor day, n (%)
All ICU 72,005 19,575 (27) 272,271 59,811 (22)
Cardiac surgery ICU 15,631 8,601 (55) 54,212 25,710 (47)
Cardiac care unit 8,807 2,095 (24) 39,732 9,310 (23)
Medical ICU 16,863 2,864 (17) 57,782 8,397 (15)
Surgical ICU 19,997 3,846 (19) 85,065 10,533 (12)
Mixed ICU 10,707 2,169 (20) 35,480 5,861 (17)
Proportion of ICU on vasopressors and vasopressor days
Patients on Vasopressor (%) = Proportion of ICU on with vasopressors = (Total number of ICU on vasopressor/total number of ICU admissions) X100
Vasopressor day (%) = Proportion of ICU vasopressor days = (Total vasopressor day/total ICU day) X100
Table 3 Vasopressor Utilization Index with specific vasopressor use from 2007 to 2013
Vasopressor Average VUI ICU admission year ΔVUI (%) p
2007 2008 2009 2010 2011 2012 2013
VUInorepinephrine 0.34 0.24 0.28 0.32 0.33 0.38 0.38 0.46 +10.3 <0.001
VUIepinephrine 0.39 0.35 0.42 0.42 0.39 0.38 0.39 0.37 −0.4 0.73
VUIphenylephrine 0.13 0.20 0.16 0.11 0.13 0.11 0.10 0.08 −1.0 <0.001
VUIvasopressin 0.41 0.40 0.38 0.43 0.42 0.39 0.42 0.44 +1.3 0.13
VUIdopamine 0.16 0.17 0.16 0.14 0.14 0.18 0.17 0.14 −12.2 0.59
VUInorepinephrine = total ICU day on norepinephrine/total ICU day on vasopressor
VUIepinephrine = total ICU day on epinephrine/ total ICU day on vasopressor
VUIphenylephrine = total ICU day on phenylephrine/ total ICU day on vasopressor
VUIvasopressin = total ICU day on vasopressin/total ICU day on vasopressor
VUIdopamine = total ICU day on dopamine/ total ICU day on vasopressor
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(VUIepinephrine was 0.03 in the year 2007 and 0.06 in the
year 2013; p < 0.001). There was a decreasing trend in the
use of phenylephrine (VUIphenylephrine was 0.40 in 2007
and 0.12 in 2013; p < 0.001) and dopamine (VUIdopamine
was 0.10 in 2007 and 0.03 in 2013; p = 0.001). Vasopressin
utilization trends did not change (Additional file 1:
Table S4E and Fig. 3e).
Low-dose dopamine use in the ICU
In the cardiac care unit, use of low-dose dopamine is
still common (VUIlow-dose dopamine was 0.30) without any
decreasing trend in its utilization. In comparison, the
use of low-dose dopamine is much less frequent with a
downward trend in other ICUs over this 7 year period.
In 2013, VUIlow-dose dopamine was 0.01 in the medical, sur-
gical, and mixed ICUs and 0.06 in cardiac surgery ICU
(Additional file 1: Table S5 and Fig. 4).
Discussion
Vasoactive agents were used in about one-fourth of ICU
admissions and ICU days. Overall, vasopressin was the
most commonly used vasopressor from 2007 to 2013,
following by epinephrine, norepinephrine, dopamine,
and phenylephrine. The use of norepinephrine showed a
significant increasing trend toward becoming the most
commonly used vasopressor in all ICUs in 2013.
Fig. 1 Trend of specific vasopressor use in all ICUs from 2007 to 2013. Note: SSC = Surviving Sepsis Campaign
Fig. 2 Relative changes in each VUI over the course of study based on ICU type. Note: * = statistically significant
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An increasing trend in the use of norepinephrine in all
ICUs is not surprising. Norepinephrine has been recom-
mended as the first choice among vasoactive agents by the
Surviving Sepsis Campaign since 2004 [11, 26, 27]. The
increasing awareness and adoption of Surviving Sepsis
Campaign are likely to have an impact on the choice of
vasopressor utilization in ICU [28, 29]. In 2010, a multi-
center randomized trial subgroup analysis demonstrated
that patients with cardiogenic shock who received dopa-
mine had a higher mortality compared to norepinephrine
[14]. These two examples offer significant insight into the
rise in the rate of the norepinephrine use after 2010.
Fig. 3 a Trend of specific vasopressor use in Cardiac Surgery ICU from 2007 to 2013. b Trend of specific vasopressor use in Cardiac Care Unit
from 2007 to 2013. c Trend of specific vasopressor use in Medical ICU from 2007 to 2013. d Trend of specific vasopressor use in Surgical ICU from
2007 to 2013. e Trend of specific vasopressor use in Mixed ICU from 2007 to 2013
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Following the SOAP-II trial [14], De Backer and col-
leagues conducted a meta-analysis [15] to compare the
use of dopamine versus norepinephrine in the treatment
of septic shock. They demonstrated that dopamine admin-
istration was associated with greater mortality and a
higher incidence of arrhythmia compared to norepineph-
rine. Dopamine not only provides different effects at vary-
ing dosages [30, 31], but each individual hemodynamic
responses is different to this vasoactive agent [32, 33]. For
this reason, the Surviving Sepsis Campaign suggests dopa-
mine not to be used as an alternative to norepinephrine in
septic shock [11]. In addition, low-dose dopamine is rec-
ommended not to be used as a renal-protective strategy.
Our study demonstrated a significant downward trend in
the dopamine use in medical and mixed ICUs where the
septic shock was expected to be the most common reason
for vasopressor use. Interestingly, we found that the use of
dopamine is only minimally reduced in all ICUs. Despite a
decreasing trend in the use of dopamine in medical, surgi-
cal, cardiac surgery and mixed ICUs, our study shows
dopamine is still the most commonly used vasopressor
agent in the cardiac care unit.
Approximately one-third of patients with septic shock
are vasopressin deficient [34, 35]. Although vasopressin,
especially in high doses, has been demonstrated to be
very effective, concerns exist regarding its adverse effects
on peripheral, intestinal, and renal circulation [36–38].
Vasopressin was the most commonly used vasopressor
from 2007 to 2013 in all ICUs. This was mainly due to
an increasing trend in vasopressin use in Cardiac surgery
ICU. In contrast, there was a decreasing trend in vaso-
pressin use in Medical and Surgical ICU. The VASST
trial showed in patients with septic shock, low-dose
vasopressin did not decrease mortality rates when com-
pared to norepinephrine [13]. Given being more costly
with unclear benefit, vasopressin might lose its favor for
use in septic shock. The Surviving Sepsis Campaign rec-
ommended against the use of vasopressin as a single ini-
tial vasopressor for septic shock [11].
The future use of vasopressors in ICUs may change as
a result of recent randomized controlled trials conducted
by ProCESS investigators [39] from the United States
and ARISE investigators from Australia & New Zealand
[40, 41]. Early Goal Directed Therapy (EGDT) and the
outcomes of patients with septic shock were studied in
all three trials. All studies found that EGDT did not re-
duce all-cause mortality in critically ill patients with
early septic shock. In addition, titrating therapy to cen-
tral venous pressure or central oxygen saturation was
not more effective than usual care in patients with se-
vere sepsis [42]. These recent findings indicate that
modification to the previously accepted EGDT algorithm
may result in as much as a 10–15 % reduction in the
overall use of vasopressor for severe sepsis and septic
shock. The SEPSISPAM investigators [18] recently con-
ducted a multicenter trial in 776 patients with septic
shock to undergo resuscitation with a high-target MAP
of 80 to 85 mmHg or low-target MAP of 65 to
70 mmHg. Although no clear benefit to higher MAP tar-
gets was found in the general population with septic
shock, this study showed a decrease in the incidence of
acute kidney injury and the need for renal replacement
therapy in the patients with chronic hypertension when
they were assigned to higher MAP arm. If future studies
confirm this finding, it has the potential to change the
rate of vasopressor utilization in the ICUs.
There are many potential explanations as to the cause
of the changes in vasopressor utilization observed in this
study. These explanations include temporal changes in
standard practices of care, staffing changes, staffing
preferences, and patient characteristics. Stratification by
specific patient characteristics, such as primary diagnosis
Fig. 4 Trend of the use of low-dose dopamine (<3 mcg/kg/min) in ICU subgroups
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(septic shock, cardiogenic shock), and comorbid diagno-
ses may further explain these differences. Temporal
changes in stratification of specific patient characteristics
may be present as well. However, the cause of the obser-
vations of this study ultimately remains unknown. Thus,
further study is required to understand the contribution
of each of these potential causal relationships to these
observations.
This study has several limitations. 1) This is a single-
center, retrospective study. This limits the generalizability
of some results, especially to the non-academic medical
setting. In addition, the majority of included patients were
post-cardiac surgery patients. 2) Causes or types of shock,
as well as patient comorbidities, may affect the choice of
vasopressors used. Although these factors may partly ex-
plain variations in vasopressor use, we did not investigate
the use of vasopressor in each type of shock because the
determination of shock type was not trivial, particularly in
a retrospective study. For example, type of shock was
often unknown, or multiple types of shock occurred sim-
ultaneously. As the severity of illness was not changed
during the course of study, we believe changes in the use
of vasopressors are mainly due to the growing knowledge
of the nature of each vasopressor in critical illness.
On the other hand, our study carries several strengths.
To our knowledge, this is the first study to report the tem-
poral trend in utilization of each vasopressor in a cohort of
ICU patients. As our center covers a very broad referral
base, the diversity of patients and their underlying patholo-
gies provided appropriate depth to our findings. Multidis-
ciplinary care provided in our ICUs limits individualized
choices for vasoactive agents. Our sample size is rather
large and this allows appropriate subgroup analyses on the
basis of ICU type that provide additional insight of vaso-
pressor utilization in each specific ICU type.
Conclusions
Utilization of vasoactive medications has changed over
the past decade. This could be due to the growth of the
knowledge regarding the performance of each vasoactive
agent. Although we found vasopressin was the most
commonly used vasopressor from 2007 to 2013, nor-
epinephrine has taken its place as the most commonly
used vasopressor in the ICUs, as of 2013. We also noted
dopamine is still used very often in the cardiac care unit.
Our study provides a large perspective view of vasoactive
agent utilization which could be utilized in the future
trials to improve the choices if these agents based on
each patients population.
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